Belinostat is a prescription medication used to treat certain types of cancer, including peripheral T-cell lymphoma (PTCL). Belinostat is a type of chemotherapy drug known as a histone deacetylase (HDAC) inhibitor. It works by blocking the action of certain enzymes that help cancer cells grow and multiply. Belinostat is given intravenously (into a vein) and is usually administered once a day for five consecutive days every three weeks. Common side effects of Belinostat include nausea, fatigue, constipation, and diarrhea.
Belinostat, also known by the brand name Beleodaq, is a medication used to treat relapsed or refractory peripheral T-cell lymphoma (PTCL). Here's a detailed description of its key characteristics:
Purpose:
- Belinostat is specifically indicated for adults with relapsed or refractory PTCL, a type of cancer that affects lymphocytes (a type of white blood cell) called T cells, primarily in the lymph nodes and other lymphatic tissues.
- "Relapsed" refers to cancer that returns after treatment, while "refractory" indicates cancer that does not respond to initial treatment.
Mechanism of Action:
- Belinostat belongs to a class of drugs called histone deacetylase (HDAC) inhibitors. These drugs work by blocking the activity of enzymes known as histone deacetylases (HDACs). HDACs are involved in regulating gene expression by modifying the structure of chromatin, which is the complex of DNA and proteins that makes up chromosomes.
- By inhibiting HDACs, belinostat alters the expression of various genes, including those involved in cell growth, survival, and differentiation. This can lead to the death of cancer cells and inhibition of tumor growth.
Administration:
- Belinostat is administered orally (by mouth) in the form of capsules.
- The typical dosage and schedule are determined by the doctor based on individual factors like the patient's weight, overall health, and response to the medication.
Important Considerations:
- Belinostat can cause serious side effects, including:
- Low blood cell counts: This can increase the risk of infections and bleeding. Close monitoring of blood cell counts is essential during treatment.
- Gastrointestinal (GI) side effects: These can include nausea, vomiting, diarrhea, and loss of appetite.
- Fatigue
- Neurological (nervous system) effects: These can include numbness, tingling, and weakness in the hands and feet.
- Embryo-fetal toxicity: Belinostat can harm an unborn baby, so it is contraindicated in pregnant women.
Overall:
Belinostat offers a treatment option for patients with relapsed or refractory PTCL. However, its use requires careful consideration due to the potential for serious side effects and the need for close monitoring by a healthcare professional. It is crucial to consult with a doctor to determine if belinostat is the right treatment option for your individual case.